Project description DEENESFRITPL Selectively enhancing antibodies through light irradiation Monoclonal antibodies have been considered a significant weapon against cancer since the beginning of the 20th century. After decades of research, medicine has managed to eliminate their adverse reactions to patients and develop revolutionary cancer therapies. The EU-funded ALISE project will focus on the possibility of boosting the anticancer activity only in tumours. To this aim, researchers will design and synthesise light-controllable conjugates of monoclonal antibodies with peptides whose anticancer activity can be enhanced in tumours by irradiation with light. In this project, seven leading institutions with significant expertise, resources and knowledge on design, synthesis and preclinical study in this field will join forces to contribute to innovative and safer therapeutic strategies. Show the project objective Hide the project objective Objective Project ALISE (Antibody Light-Induced Selectivity Enhancement) will integrate the expertise, resources and knowledge of participating Institutions focusing on design, synthesis and preclinical study of conjugates of monoclonal antibodies with peptides whose anti-cancer activity can be enhanced in tumours by irradiation with light (LC-APCs). The possibility to boost the anti-cancer activity only in tumours, multiplied by targeting cancer cells by antibodies will be a basis for innovative and safer therapeutic strategies. Four of seven participating Institutions successfully collaborated in the field of light-controllable anticancer peptides, but this Project will widen the scope of collaboration, both in terms of the research field and collaborating Institutions. The participating Institutions are complementary in their expertise and know-how: the University of Cambridge will contribute with its know-how in design and preparation of antibodies. Light controllable peptides will be designed at Latvian Institute of Organic Synthesis and Karlsruhe Institute of Technology, synthesized, then loaded onto the antibodies in Cambridge. Company Enamine will perform initial screening of the conjugates in vitro and assess their safety. National Cancer Institute of Ukraine will contribute with its expertise in immunology, Cancer Center Amsterdam – with its expertise and knowledge in preclinical and clinical oncology. Lumobiotics GmbH will complement the consortium with its expertise in drug development. Integration of this potential will be achieved through research staff exchange and other activities organized in five work packages: 1) design and synthesis of novel light-controllable peptides as anti-cancer antibody payloads; 2) preparation and characterization of peptide conjugates with a model antibody; 3) biological screening of model LC-APCs; 4) preclinical evaluation of the LC-APCs aiming at treatment of human PDAC; 5) management, training, communication, dissemination. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesbiochemistrybiomoleculesmedical and health sciencesbasic medicineimmunologymedical and health sciencesclinical medicineoncology Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.3. - Stimulating innovation by means of cross-fertilisation of knowledge Topic(s) MSCA-RISE-2020 - Research and Innovation Staff Exchange Call for proposal H2020-MSCA-RISE-2020 See other projects for this call Funding Scheme MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) Coordinator ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE Net EU contribution € 303 600,00 Address 78 chervonotkatska str. 02094 Kyiv Ukraine See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (6) Sort alphabetically Sort by Net EU contribution Expand all Collapse all KARLSRUHER INSTITUT FUER TECHNOLOGIE Germany Net EU contribution € 73 600,00 Address Kaiserstrasse 12 76131 Karlsruhe See on map Region Baden-Württemberg Karlsruhe Karlsruhe, Stadtkreis Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE United Kingdom Net EU contribution € 27 600,00 Address Trinity lane the old schools CB2 1TN Cambridge See on map Region East of England East Anglia Cambridgeshire CC Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 LATVIJAS ORGANISKAS SINTEZES INSTITUTS Latvia Net EU contribution € 55 200,00 Address Aizkraukles 21 LV-1006 Riga See on map Region Latvija Latvija Rīga Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 NATIONAL CANCER INSTITUTE Ukraine Net EU contribution € 55 200,00 Address 33/43 lomonosova street 03022 Kiyv See on map Activity type Research Organisations Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 LUMOBIOTICS GmbH Germany Net EU contribution € 165 600,00 Address Auerstrasse 2 76227 Karlsruhe See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Baden-Württemberg Karlsruhe Karlsruhe, Stadtkreis Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 STICHTING VUMC Netherlands Net EU contribution € 64 400,00 Address De boelelaan 1117 1081 HV Amsterdam See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00